Xalacom outperforms Cosopt in glaucoma
Pharmacia's Xalacom (latanoprost and timolol) is more effective atreducing intraocular pressure in patients with glaucoma than a rival drug, Merck & Co's Cosopt (dorzolamide and timolol), according to the results of a 251-patient study reported at the annual conference of the Association for Research in Vision and Ophthalmology held in Fort Lauderdale, Florida, USA.
After three months of treatment, Xalacom was associated with an average reduction in IOP of 9.4mmHg, compared to 8.4mmHg with Cosopt, a statistically-significant difference (p<0.005).
Meantime, another trial presented at the ARVO meeting has found that patients on monotherapy for glaucoma, including beta blockers and prostaglandin derivatives, can experience an improvement in IOP when switched to Pharmacia's Xalatan (latanoprost) for at least six weeks. The average improvement in IOP in patients who swapped over was 3mmHg (
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze